AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02831426 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage with Acellular Dermal Matrix (CELLIS® Breast)
Description: After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by an ADM (CELLIS® Breast, MECCELLIS BIOTECH, 40 rue Chef de Baie, 17000, La Rochelle FRANCE) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
Study NCT01511211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
Study NCT01511211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
Study NCT00450034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drug - oriented multifaceted intervention
Description: oriented multifaceted intervention
Study NCT00901810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Apex Locator
Description: Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
Study NCT00901810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Radiography
Description: Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
Study NCT03327740 — intervention group
Intervention type: DRUG
Intervention: DTG based ARV regimen with ABC
Description: ARV regimens containing DTG and ABC
Study NCT03327740 — intervention group
Intervention type: DRUG
Intervention: DTG based ARV regimen without ABC
Description: DTG based ARV regimens that do not contain ABC
Study NCT03327740 — intervention group
Intervention type: DRUG
Intervention: RAL or EGV based ARV regimens with ABC
Description: RAL or EGV based regimens containing ABC
Study NCT03327740 — intervention group
Intervention type: DRUG
Intervention: RAL or EGV based regimens without ABC
Description: RAL or EGV based ARV regimens that do not contain ABC
Study NCT03327740 — intervention group
Intervention type: DRUG
Intervention: Any other DTG based ARV regimen as monotherapy
Description: Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
Study NCT03467035 — intervention group
Intervention type: OTHER
Intervention: Inflammasone
Description: Serum level of cytokine and RT-PCR for PBMC
Study NCT02831426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)
Description: After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by a Titanium Coated Polypropylene Mesh (TiLOOOP® Bra, pfm medical, ag Wankelstraße 60 ,50996 Köln GERMANY) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
Study NCT03842644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tension reduction device
Description: Continue using this device for 3 months post surgery.
Study NCT04122170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
Study NCT04122170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
Study NCT04122170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (ASA) Oral Tablet - Pre-Treatment
Description: Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
Study NCT04122170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin (ASA) Oral Tablet - Pre-Treatment
Description: Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
Study NCT04122170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bentracimab (PB2452) Infusion
Description: Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration~In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion.
Study NCT04122170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% Sodium chloride) infusion
Description: 0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
Study NCT01196962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central venous catheter
Description: Central venous catheter insertion to subclavian vein
Study NCT00908037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: thrombopoietin receptor agonist
Study NCT00908037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for comparison
Study NCT02661672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Device
Description: The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system.
Study NCT02661672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artemis Device
Description: The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.
Study NCT00642863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate (liquid) + vitamins A and D
Description: a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
Study NCT00642863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamins A and D
Description: a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
Study NCT00642863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (liquid)
Description: Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
Study NCT01364701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil 100 mg
Description: 4 tablets for on demand use
Study NCT01364701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 20 mg
Description: 4 tablets on demand
Study NCT01364701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination half of maximal dose for sildenafil & tadalafil
Description: 4 tablets on demand
Study NCT03046524 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: Data between the years of 1/1/2002 and 12/31/2013 analyzed.
Study NCT03530670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral midazolam
Description: 0.5 mg/kg oral midazolam administered 20 minutes before anesthesia induction
Study NCT03530670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.
Description: Patients will be watched a short movie (at URL:~http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.Wd-YhFu0PIU) 20 minutes before induction.
Study NCT03530670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Playing smartphone game
Description: Patients will be played with smartphone (angry birds, subway surfers or snail Bob) 20 minutes before induction
Study NCT02153060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
Study NCT02153060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
Study NCT03336385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Naxus
Description: Non-digestible polysaccharides arabinoxylan (Naxus)
Study NCT03336385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oatwell
Description: Non-digestible polysaccharides oat beta-glucan (Oatwell)
Study NCT03336385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin as placebo
Study NCT01033318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809
Study NCT00389922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)
Study NCT00389922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)
Study NCT00389922 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: comparative genomic hybridization
Description: Molecular correlative study
Study NCT00389922 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Molecular correlative study
Study NCT00389922 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Molecular correlative study
Study NCT00389922 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Molecular correlative study
Study NCT01033318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Losartan
Description: single oral doses of 100 mg Losartan
Study NCT00389922 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Molecular correlative study
Study NCT00389922 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Molecular correlative study
Study NCT00389922 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Description: Molecular correlative study
Study NCT00389922 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Molecular correlative study
Study NCT00389922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Molecular correlative study
Study NCT00389922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Molecular correlative study
Study NCT00389922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)
Study NCT00389922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine ditartrate
Description: Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
Study NCT01811693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerly Trinitrate
Description: 5mg/24hour (0.2mg/hour) transdermal
Study NCT01811693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerly Trinitrate
Description: 10mg/24hour (0.4mg/hour) transdermal
Study NCT01811693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerly Trinitrate
Description: 0.4 mg sublingual single metered spray
Study NCT01244503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Octanoate Breath Test
Description: 100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
Study NCT00762112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559
Description: TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
Study NCT01082497 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness training
Description: A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
Study NCT01082497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
Study NCT03822104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants start with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5 if the infants only receive DM. The intervention lasts until the infants reach postmenstrual age (PMA) 35+6 weeks or in no-need of fortification due to sufficient growth, whichever comes first.
Study NCT03822104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FM85
Description: Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed until discharge.
Study NCT02333084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PRN Joint Health Formula
Study NCT02333084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02333084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PRN Flex Omega Benefits® combination
Study NCT02200510 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-management intervention for Adolescents with SCD
Description: Chronic Disease Self-Management Program
Study NCT02200510 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Portal Intervention for Adolescents with SCD
Description: MyChart for SCD intervention
Study NCT04454632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: affected arm stay behind the mirror while exercising
Study NCT04454632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual feedback
Description: visual feedback from mirror
Study NCT04692285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single 5 mg dose of Zolpidem.
Study NCT01033318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809
Study NCT01667159 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
Study NCT04158206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal voice
Description: Recording in the intensive care unit quiet and separate consultation room. For infants in the 'maternal voice group,' mothers were asked to tape what the mother wants to say to their babies and read of a child book from the independent publish, 'Xiao Qi's yellow persimmon' which talk about the mother who has a premature infants how to take caring of their baby. After reviewing the quality of the recording, the mother's voice recordings are compiled for 13 minutes with Sound Organizer. 2 , and the volume of the sound standard according to the American Academy of Pediatrics guidelines is 60 decibels in the incubator.
Study NCT04692285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single dose of placebo.
Study NCT02929056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AmnioExCel dressing and compression therapy
Description: Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
Study NCT02929056 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SOC alginate dressing and compression therapy
Description: Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
Study NCT00805675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600 mg monotherapy supplied in film-coated tablets.
Study NCT03677752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GP_Posit
Description: Mother-infant dyads allocated to this arm will receive the GP_Posit intervention. The intervention consists of a guided participation intervention to positioning. Mothers will meet with the intervention nurse twice a week for the two first weeks after birth and then one a week until the infant will reach 35 weeks of gestational age. During these encounters, mothers will learn how to interpret their infant's stress and stability cues and participate in his/her care and positioning while being guided by the intervention nurse.
Study NCT00815373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide+Timolol Maleate0.5%
Description: Cosopt\* b. i. d.
Study NCT00815373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost+Timolol Maleate0.5%+Lytears
Description: Xalacom\* QHS
Study NCT01959087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single port surgery
Description: Single port surgery can be converted in multiport surgery if necessary
Study NCT01959087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiport surgery
Study NCT01959087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiport surgery
Study NCT01281592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOR-253 HCl
Description: LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
Study NCT01480193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound Based and Educational Therapies
Description: The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
Study NCT01480193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sound Based and Educational Therapies
Description: The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
Study NCT02399514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnographic diagnostic
Description: Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment